Mycofoli 540 Tablet contains Mycophenolate Sodium 540 mg, a potent immunosuppressant widely used in organ transplant medicine to prevent graft rejection.
This tablet works by inhibiting inosine monophosphate dehydrogenase (IMPDH), suppressing T- and B-lymphocyte proliferation and reducing immune-mediated damage to transplanted organs. It is ideal for patients requiring mid- to high-dose immunosuppression under strict medical supervision.
Clinically, Mycofoli 540 Tablet is prescribed in renal, hepatic, and cardiac transplant regimens, often as part of combination immunosuppressive therapy to ensure graft stability and long-term transplant success.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospitals, transplant centers, specialty clinics, and pharmacies managing advanced post-transplant immunosuppressive therapy.
Common side effects may include diarrhea, nausea, abdominal discomfort, headache, and increased susceptibility to infections. Rare but serious adverse effects include leukopenia, anemia, thrombocytopenia, severe infections, and hypersensitivity reactions.
Mycofoli 540 Tablet is indicated for the prevention of organ transplant rejection in renal, cardiac, or hepatic transplant recipients. It is also used in the management of selected autoimmune disorders, as prescribed by a specialist.
Use Mycofoli 540 Tablet strictly under medical supervision. Regular monitoring of complete blood count, liver and kidney function, and signs of infection is essential. Inform your doctor if you have active infections, bone marrow suppression, or are taking other immunosuppressive medications. Avoid live vaccines during therapy and seek immediate medical attention if persistent fever, unusual bleeding, or severe infections occur.
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.